The Yin and Yang of Viruses and Interferons

Overview

Journal Trends Immunol

Specialty Allergy & Immunology

Date 2012 Feb 11

PMID 22321608

Citations 69

Authors

Ben X Wang

Eleanor N Fish

Affiliations

Soon will be listed here.

Abstract

Interferons (IFNs)-α/β are critical effectors of the innate immune response to virus infections. Through activation of the IFN-α/β receptor (IFNAR), they induce expression of IFN-stimulated genes (ISGs) that encode antiviral proteins capable of suppressing viral replication and promoting viral clearance. Many highly pathogenic viruses have evolved mechanisms to evade an IFN response and the balance between the robustness of the host immune response and viral antagonistic mechanisms determines whether or not the virus is cleared. Here, we discuss IFNs as broad-spectrum antivirals for treatment of acute virus infections. In particular, they are useful for treatment of re-emerging virus infections, where direct-acting antivirals (DAAs) have limited utility due to DAA-resistant mutations, and for newly emerging virus strains in which the time to vaccine availability precludes vaccination at the onset of an outbreak.

Citing Articles

Downregulation of IRF7-mediated type-I interferon response by LmCen parasites is necessary for protective immunity.

Sepahpour T, Alshaweesh J, Azodi N, Singh K, Ireland D, Valanezhad F NPJ Vaccines. 2024; 9(1):250.

PMID: 39702382 PMC: 11659581. DOI: 10.1038/s41541-024-01032-6.

Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2.

Saikh K, Anam K, Sultana H, Ahmed R, Kumar S, Srinivasan S Int J Mol Sci. 2024; 25(15).

PMID: 39125989 PMC: 11313481. DOI: 10.3390/ijms25158421.

Bacteria colonization and gene expression related to immune function in colon mucosa is associated with growth in neonatal calves regardless of live yeast supplementation.

Nishihara K, Villot C, Cangiano L, Guan L, Steele M J Anim Sci Biotechnol. 2024; 15(1):76.

PMID: 38835065 PMC: 11151515. DOI: 10.1186/s40104-024-01030-7.

IFNα Subtypes in HIV Infection and Immunity.

Karakoese Z, Ingola M, Sitek B, Dittmer U, Sutter K Viruses. 2024; 16(3).

PMID: 38543729 PMC: 10975235. DOI: 10.3390/v16030364.

The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors.

Esteban-Vazquez A, Steiner M, Castaneda E, Andreu-Vazquez C, Thiussard I, Somodevilla A Vaccines (Basel). 2023; 11(10).

PMID: 37897012 PMC: 10610564. DOI: 10.3390/vaccines11101610.

References

Wong V, Wong G, Yan K, Chim A, Chan H, Tse C . Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010; 51(6):1945-53. DOI: 10.1002/hep.23568. View

Siu K, Kok K, Ng M, Poon V, Yuen K, Zheng B . Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J Biol Chem. 2009; 284(24):16202-16209. PMC: 2713514. DOI: 10.1074/jbc.M109.008227. View

Runkel L, de Dios C, Karpusas M, Baker D, Li Z, Zafari M . Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J Interferon Cytokine Res. 2001; 21(11):931-41. DOI: 10.1089/107999001753289541. View

Korn A, Rose D, Fish E . Three-dimensional model of a human interferon-alpha consensus sequence. J Interferon Res. 1994; 14(1):1-9. DOI: 10.1089/jir.1994.14.1. View

Baril M, Racine M, Penin F, Lamarre D . MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J Virol. 2008; 83(3):1299-311. PMC: 2620913. DOI: 10.1128/JVI.01659-08. View

Sanjo M, Saito T, Ishii R, Nishise Y, Haga H, Okumoto K . Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C. J Med Virol. 2010; 82(8):1364-70. DOI: 10.1002/jmv.21818. View

Jia D, Rahbar R, Fish E . Interferon-inducible Stat2 activation of JUND and CLDN4: mediators of IFN responses. J Interferon Cytokine Res. 2007; 27(7):559-65. DOI: 10.1089/jir.2007.0014. View

Liang S, Wei H, Sun R, Tian Z . IFNalpha regulates NK cell cytotoxicity through STAT1 pathway. Cytokine. 2003; 23(6):190-9. DOI: 10.1016/s1043-4666(03)00226-6. View

Kumaki Y, Day C, Wandersee M, Schow B, Madsen J, Grant D . Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochem Biophys Res Commun. 2008; 371(1):110-3. PMC: 2441846. DOI: 10.1016/j.bbrc.2008.04.006. View

10.

Huang I, Bailey C, Weyer J, Radoshitzky S, Becker M, Chiang J . Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011; 7(1):e1001258. PMC: 3017121. DOI: 10.1371/journal.ppat.1001258. View

11.

Loutfy M, Blatt L, Siminovitch K, Ward S, Wolff B, Lho H . Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003; 290(24):3222-8. DOI: 10.1001/jama.290.24.3222. View

12.

Devaraj S, Wang N, Chen Z, Chen Z, Tseng M, Barretto N . Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem. 2007; 282(44):32208-21. PMC: 2756044. DOI: 10.1074/jbc.M704870200. View

13.

Gao L, Yu S, Chen Q, Duan Z, Zhou J, Mao C . A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine. 2010; 28(28):4445-51. PMC: 7115383. DOI: 10.1016/j.vaccine.2010.03.062. View

14.

Paladino P, Collins S, Mossman K . Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to block IRF3-mediated innate immune responses. PLoS One. 2010; 5(4):e10428. PMC: 2861674. DOI: 10.1371/journal.pone.0010428. View

15.

Thomas C, Moraga I, Levin D, Krutzik P, Podoplelova Y, Trejo A . Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 2011; 146(4):621-32. PMC: 3166218. DOI: 10.1016/j.cell.2011.06.048. View

16.

Kumar H, Kawai T, Akira S . Pathogen recognition by the innate immune system. Int Rev Immunol. 2011; 30(1):16-34. DOI: 10.3109/08830185.2010.529976. View

17.

Langston A, Redei I, Caliendo A, Somani J, Hutcherson D, Lonial S . Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood. 2002; 99(3):1085-8. DOI: 10.1182/blood.v99.3.1085. View

18.

van der Vries E, Schutten M, Boucher C . The potential for multidrug-resistant influenza. Curr Opin Infect Dis. 2011; 24(6):599-604. DOI: 10.1097/QCO.0b013e32834cfb43. View

19.

Fish E, Banerjee K, Stebbing N . Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochem Biophys Res Commun. 1983; 112(2):537-46. DOI: 10.1016/0006-291x(83)91498-5. View

20.

Karti S, Ovali E, Ratip S, Cetiner M, Direskeneli H, Bayik M . Effect of interferon-alpha(2a) on neutrophil adhesion and phagocytosis in chronic myeloid leukemia and Behçet's disease. Clin Rheumatol. 2002; 21(3):211-4. DOI: 10.1007/s10067-002-8288-1. View